Dose selection study for PRT318. C57Bl/6 mice (n = 4/group) were orally dosed twice a day for 7 days with either 10 mg/kg or 30 mg/kg of body weight at time points indicated by arrows. PRP from PRT318-treated mice were exposed to convulxin (250 ng/mL), and platelet aggregation was measured as a pharmacodynamic marker of antiplatelet activity. The graph represents the percentage inhibition of aggregation at each time point examined. For clarity, error bars are not shown.